IL33 and neoplasm: Apart from triggering the IL-33/ST2 signaling to augment cancer immunotherapy, a number of studies showed the blockade of IL-33, ST2, or both resulted in growth inhibition of tumors [120,209,210] in association with reduced accumulation of ST2+ tumor-promoting cells, such as Treg, TAM, and IL17RB+ILC2.